Accuracy of systolic aortic regurgitation in the diagnosis of heart failure: a predictive approach.

BACKGROUND: Systolic aortic regurgitation (SAR) is a curious phenomenon that has been found to be associated with heart failure (HF). We aimed to determine de diagnostic value of SAR as a black box predictive tool in patients with suspected HF admitted to hospital with dyspnea as leading symptom. METHODS AND RESULTS: Cross-sectional study including 269 consecutive patients admitted to hospital with dyspnea as leading symptom without definite clinical diagnosis. SAR was defined by echocardiography as the presence of blood flow from the aorta to the left ventricular outflow tract during a complete systole. The reference standard was the presence of HF diagnosis at discharge. SAR was present in 9 (3.3%) patients. Prevalence of HF was 40.3%. Specificity of SAR in the diagnosis of HF was high at 99.4% (95% CI 96.5-99.9%). Sensitivity was 7.5% (95% CI 3.9-14.2%). Positive predictive value (PPV) was 88.9% (95% CI 56.5-98.0%). Positive likelihood ratio was 11.85. Estimated PPV of SAR was significantly higher than 50% for any hypothetical prevalence of HF. CONCLUSION: In patients admitted to hospital with dyspnea, the finding of systolic aortic regurgitation in echocardiography has a high PPV for HF diagnosis at discharge.

Echocardiographic study in cirrhotic patient candidates for liver transplantation.

We studied 81 cirrhotic patients who were candidates for liver transplantation to evaluate frequently detected cardiac alterations by echocardiographic study. Patients were distributed into three groups: group 1 comprised alcoholic cirrhotic patients (n = 40); group 2, viral cirrhotic patients (hepatitis C or B virus) (n = 35); and group 3, patients with primary biliary cirrhosis (n = 6). Cardiac chambers and diastolic functions were estimated by two-dimensional transthoracic echocardiography in M mode and Doppler. The most frequently detected cardiac structural alterations were left atrial diameter enlargement in 100% of the women and 40% of the men in group 1; 87.5% of the women and 15.4% of the men in group 2; and 33.3% of the women in group 3. Interventricular wall thickness enlargement in 50% of the women and 27.8% of the men in group 1, 25% of the women and 30.8% of the men in group 2, and 16.4% of the women in group 3. The prevalence of diastolic dysfunction was 45% in group 1, 32.3% in group 2, and 16.4% in group 3 (P > .05). There were no significant differences between the groups in cardiac chamber dimensions, left ventricular wall thickness, or prevalence of diastolic dysfunction.

Hepatopulmonary syndrome among cirrhotic candidates for liver transplantation.

This study assess of hepatopulmonary syndrome (HPS) prevalence and the influence of etiology among cirrhotic patients due to an alcoholic or viral etiology. We examined the records of patients were distributed as Group 1, alcoholic (n = 40) and Group 2, hepatic cirrhosis of viral etiology (n = 35). Hepatic cirrhosis status was estimated by CHILD and MELD scores. Presence of clinical ascites spell out was noted as well as size and diastolic functions of the cardiac chambers using two-dimensional transthoracic echocardiography in M mode and by Doppler. HPS was studied with agitated saline serum and intravenous contrast administration. HPS was considered to be present when serum or contrast passed to the left chamber before the 5th cardiac cycle. There was no significant differences among related to sex, age, cirrhosis status or ascites. HPS frequency was 35% in Group 1 versus 64.7% among Group 2-Patients (P = .01). Taking into account the results, we concluded that HPS frequency was related to cirrhotic etiology. Upon multivariate analysis a patients with cirrhosis from viral etiology showed significantly increased HPS frequency compared with those displaying cirrhosis of an alcoholic etiology.

Preoperative natriuretic peptide-B values and ascites in male liver transplant recipients.

Plasma preoperative values of natriuretic B peptide (pro-BNP) were correlated with ascites in men experiencing hepatic cirrhosis due to different etiologies on the active waiting list for liver transplantation. The study was performed in 54 male recipients of a liver transplant. Written informed consent was obtained from the patients or their relatives, and the study protocol was approved by our local Clinical Research (Ethics) Committee. Male patients were classified into two groups: group 1 included patients with alcoholic hepatic cirrhosis (n = 30) distributed as 19 men with no ascites, four with nonrefractory ascites, and seven with refractory ascites; group 2 included cases of viral hepatitis cirrhosis (n = 24) distributed as 13 men with no ascites, nine with non-refractory ascites, and two with refractory ascites. A group of six healthy male volunteers was used to establish normal (basal) values of pro-BNP and left auricular diameter (LAD). Pro-BNP values were determined in plasma samples by an electrochemiluminiscence immunoassay. Pro-BNP plasma levels in patients with alcoholic cirrhosis were threefold greater among patients with no ascites or no refractory ascites compared with healthy men, whereas pro-BNP values were fivefold enhanced among alcoholic patients with refractory ascites. The viral hepatitis cirrhosis group showed pro-BNP plasma values 1.5-fold enhanced in men with no ascites, whereas pro-BNP reached fivefold with either nonrefractory or refractory ascites. The enhanced pro-BNP plasma levels indicated advanced hepatic degradation, seemingly related to the presence of refractory ascites associated with cirrhosis.

Recovery of global systolic function after primary angioplasty. Influence of coronary flow velocity reserve measured by transthoracic echocardiography.

BACKGROUND: Our objective were to know whether coronary flow velocity reserve measured by transthoracic Doppler echocardiography, as marker of microvascular integrity, affects the recovery of global systolic function. Secondly, we intended to define the best cut-off point of coronary flow velocity reserve to predict recovery of global systolic function. METHODS: We studied 57 patients with coronary flow recorded by transthoracic Doppler echocardiography, after suffering a first anterior acute myocardial infarction and undergoing a successful primary percutaneous coronary intervention (TIMI 3 flow). We measured, at discharge and at 1 month: ejection fraction, volume indexes and anterior wall motion score index. Coronary flow in left anterior descending artery was detected by transthoracic Doppler echocardiography and coronary flow velocity reserve was calculated. RESULTS: After applying ROC curves, 1.54 was the best cut-off value of coronary flow velocity reserve for detection of recovery of global systolic function. Ejection fraction only increased significantly in patients with normal coronary flow velocity reserve. Only end-systolic volume index increased significantly at 1 month in patients with impaired coronary flow velocity reserve. CONCLUSION: We showed that coronary flow velocity reserve, measured by transthoracic Doppler echocardiography, influence the recovery of global systolic function, mainly by ventricular dilation. Furthermore, a quite lower value of coronary flow velocity reserve than that used for diagnostic purpose should be used to predict improvement of systolic function.

Mycophenolate mofetil-induced neutropenia in liver transplantation.

BACKGROUND: Mycophenolate mofetil (MMF) is a potent, safe immunosuppressive agent for rescue therapy of acute and chronic rejection in orthotopic liver transplant recipients. It helps to reduce the serious toxic side effects of calcineurin inhibitors (CNIs). The side effects of MMF, such as bone marrow toxicity, have been reported. Herein we report four patients who underwent liver transplantation and developed neutropenia while receiving MMF. METHODS: Between April 2002 and October 2003, we performed 24 liver transplants in 25 patients. Eighteen patients were given MMF for the following reasons: renal failure in nine (50%); treatment of acute rejection in three (16.6%); primary prophylaxis of rejection in five (27.7%); and CNI withdrawal in one (5.5%). RESULTS: Of the 18 patients treated with MMF, there were 11 men (61.1%) and seven women (38.8%), with an overall mean age of 55.5 years. This therapy was ceased in four patients due to neutropenia (22%). Discontinuation of MMF was followed by a rapid and spontaneous rise in neutrophils in two patients. Granulocyte colony stimulating factor (GCSF) was administered to one patient and in another a bone marrow biopsy was performed due to persistent anemia, leukopenia, and thrombocytopenia. The mean time from starting MMF to the development of neutropenia was 4 months. Only the third patient showed elevated levels of MMF. CONCLUSIONS: MMF is a potent immunosuppressive agent in liver transplantation. However, because serious hematologic toxicity has been reported, we recommend caution in administration and careful monitoring of blood levels.

[Intrahepatic cholestasis of pregnancy. Maternofetal implications]. / Colestasis gravídica intrahepática. Implicaciones maternofetales.

OBJECTIVE: To analyze a group of pregnancies complicated by intrahepatic cholestasis in order to favour an early recognition and to decrease maternal and fetal morbid-mortality. PATIENTS AND METHODS: Retrospective study of 46 pregnancies with intrahepatic gravidic cholestasis between 1990-94. We review the most relevant epidemiologic, clinical and biological features and the obstetric and perinatal results. The study group was compared with 1652 non complicated pregnancies (control group) from the same period of time. The statistic evaluation was made with t Student and chi 2. RESULTS: The incidence was 0.18% (mean age of 27.8 +/- 6.7 years) similar to the control group, and a greater rate of primiparity (p < 0.05) and twin pregnancies (p < 0.001). The most frequent symptom was pruritus, followed by choluria (23.9%) and signs of cutaneous scratching (17.3%). Only 5 patients (10.8%) had jaundice. The GPT was greater than 100 U/1 in 29 cases (63.1%) and the GOT in 17 (37%). In 25 pregnancies (54.3%) the alkaline phosphatase exceeded 600 U/L and 28 (60.8%) had bilirubin normal values. Urinary tract infections (26%) and preterm labor (17.3%) were significantly more frequent (p < 0.001) in patients with intrahepatic cholestasis of pregnancy, as well as induced labor rate and cesarean section percentages (p < 0.001). The neonatal prognosis was significantly worse, with 10 preterm babies, 6 with 5 minutes Apgar score lower than 7, and 3 perinatal deaths. All the patients recovered their normal status after delivery. CONCLUSIONS: In intrahepatic gravidic cholestasis moderate cytolysis, infrequent jaundice and cholestasis can be important. The pregnancies should be considered of high risk, and should be managed aggressively as soon as fetal maturity allows it.

[Thyroid dysfunction in patients with chronic hepatitis C pre and post treatment with interferon]. / Disfunción tiroidea en pacientes con hepatitis crónica C pre y post tratamiento con interferón.

OBJECTIVE: The aim of this study was to evaluate the thyroid function and the dysfunction after interferon therapy in patients with chronic hepatitis C. MATERIAL AND METHODS: Between 1988 and 1994, 119 patients with chronic hepatitis C treated with interferon were reviewed 92 patients received interferon alfa for six or twelve months. 27 patients were treated with interferon beta for six months. Before, during and after interferon therapy, free thyroxine, thyroid-stimulating hormone, antimicrosomal antibodies and antithyroglobulin antibodies were measured in 51 patients. None of the patients had abnormal thyroid function or autoimmune disease before treatment. RESULTS: Among the interferon-treated patients, 6% developed biochemical evidence of thyroid dysfunction during or after therapy. Most cases had hypothyroidism. Thyroid dysfunction was statistically more frequent in the female sex, older patients and in patients who received greater total dose of interferon. In one patient the titters of antimicrosomal thyroid antibodies increased from 1/10 to 1/40 and another patient was positive in a dilution of 1/80 by the time of onset of thyroid disease. Thyroid disease (hypothyroidism) developed in (3.5%) of untreated patients with chronic hepatitis C. CONCLUSIONS: Interferon therapy can development autoimmune thyroid fenomena. Thyroid dysfunction and the presence of antithyroid antibodies before therapy can be a contraindication to the use of interferon in these patients. It is important that patients undergoing interferon therapy be tested for antithyroid antibodies and thyroid function before treatment and be monitored during the course of therapy. Also, it is important to evaluate the factors related with the development of thyroid dysfunction (age, sex, interferon dose...).

[Papillary tumor of the pancreas diagnosed by fine-needle aspiration]. / Tumor papilar de páncreas diagnosticado mediante punción aspiración con aguja fina.

We report the case of a 48 year-old woman with an epigastric palpable mass identified by abdominal echography and computed tomography as a solid pancreatic tumor. A cytology taken by fine needle aspiration guided by computed tomography was diagnostic of papillary pancreatic tumor, which was confirmed by surgical resection. We emphasize the low frequency and good prognosis of this type of tumor after surgical resection, and the utility of image techniques and fine needle aspiration to obtain a preoperative diagnosis.

[Laparoscopic diagnosis of hepatic angiomas after erroneous imaging techniques]. / Diagnóstico laparoscópico de angiomas hepáticos tras error por técnicas de imagen.

Hemangiomas are de most frequent benign liver tumours. Their clinical relevance is small but they can cause to the patient and/or the physician a great worry because can be indistinguishable from hepatic malignances. From 1991 to 1994 five patients with liver hemangiomas were diagnosed by laparoscopy after a erroneous and/or contradictory interpretation by various imaging techniques. In four cases hemangiomas resembled metastatic carcinoma of the liver, and in the other patient hemangioma was interpreted as focal nodular hyperplasia. Diagnosis and treatment are discussed.